Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10453953 | 0.93 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1PTGES2MCOLN3MAPT | |
| SCHEMBL4735500 | 0.89 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1PTGES2MCOLN3MAPT | |
| SCHEMBL4030282 | 0.86 | ALDH1A1 (0.87) | ALDH1A1L3MBTL1MCOLN3MAPTKDM4E | |
| SCHEMBL23052443 | 0.85 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1PTGES2MCOLN3MAPT | |
| SCHEMBL4781795 | 0.84 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1PTGES2MCOLN3MAPT | |
| SCHEMBL4785389 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1TSHRHTR1AHTR7 | |
| SCHEMBL4036979 | 0.80 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1MAPTKDM4EP2RX7 | |
| SCHEMBL3526582 | 0.80 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1MCOLN3MAPTKDM4E | |
| SCHEMBL9621245 | 0.79 | P2RX7 (0.52) | ALDH1A1L3MBTL1PTGES2TSHRP2RX7 | |
| SCHEMBL809747 | 0.79 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1PTGES2MCOLN3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| CN-1484633-A | N (phenylsulphonyl) glycine derivatives and their therapentic use | ʵ���Ҹ���Ү��˾ | 2004-03-24 | — | — | CN | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | ALDH1A1 73/4885L3MBTL1 4830/4885PTGES2 1116/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | ALDH1A1 2269/4885L3MBTL1 4218/4885PTGES2 1330/4885 |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | ALDH1A1 2730/4885L3MBTL1 2774/4885PTGES2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.